Technical Analysis for AVXL - Anavex Life Sciences Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 11.14 | 2.48% | 0.27 |
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Historical AVXL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -3.72% | |
| Wide Bands | Range Expansion | -3.21% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 15 hours ago |
| Outside Day | about 15 hours ago |
| Up 3% | about 18 hours ago |
| 60 Minute Opening Range Breakout | about 18 hours ago |
| Up 2% | about 18 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2021
Anavex Life Sciences Corp. Description
Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer's disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer's disease. The company's product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Cancers Chemical Compounds Neuroscience Alzheimer's Disease Alzheimer's Central Nervous System Disease Central Nervous System Diseases Piperidines Treatment Of Alzheimer's Disease Lewy Body Dementia Neuroprotection Donepezil Nootropics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.6799 |
| 52 Week Low | 3.42 |
| Average Volume | 1,330,148 |
| 200-Day Moving Average | 7.78 |
| 50-Day Moving Average | 13.26 |
| 20-Day Moving Average | 11.86 |
| 10-Day Moving Average | 11.71 |
| Average True Range | 0.75 |
| ADX | 27.34 |
| +DI | 11.69 |
| -DI | 29.65 |
| Chandelier Exit (Long, 3 ATRs ) | 12.49 |
| Chandelier Exit (Short, 3 ATRs ) | 12.59 |
| Upper Bollinger Band | 12.82 |
| Lower Bollinger Band | 10.90 |
| Percent B (%b) | 0.12 |
| BandWidth | 16.17 |
| MACD Line | -0.57 |
| MACD Signal Line | -0.49 |
| MACD Histogram | -0.0755 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.63 | ||||
| Resistance 3 (R3) | 12.52 | 11.92 | 12.38 | ||
| Resistance 2 (R2) | 11.92 | 11.54 | 11.97 | 12.30 | |
| Resistance 1 (R1) | 11.53 | 11.31 | 11.73 | 11.64 | 12.21 |
| Pivot Point | 10.93 | 10.93 | 11.03 | 10.98 | 10.93 |
| Support 1 (S1) | 10.54 | 10.55 | 10.74 | 10.64 | 10.07 |
| Support 2 (S2) | 9.94 | 10.32 | 9.99 | 9.98 | |
| Support 3 (S3) | 9.55 | 9.94 | 9.90 | ||
| Support 4 (S4) | 9.65 |
